MCB-613 exploits a collateral sensitivity in drug resistant <i>EGFR</i> -mutant non-small cell lung cancer through covalent inhibition of KEAP1
Christopher F. Bassil(Duke University), Kris C. Wood(Duke University), Kévin Jubien-Girard(Centre National de la Recherche Scientifique), Tierney M. Hall(Duke University), Cécile Favreau(Inserm), Anthony R. Martin(École Nationale Supérieure de Chimie de Montpellier), Haley M. Hutchinson(Duke University), Katherine R. Singleton(Duke University), Shane T. Killarney(Duke University), Christian Cerda-Smith(Duke University), Alexandre Puissant(Délégation Paris 5), Patrick Auberger(Inserm), Guillaume Robert(Centre Méditerranéen de Médecine Moléculaire), Kayleigh N. Askin(Duke University), Rachid Benhida(Centre National de la Recherche Scientifique), Ann Marie Pendergast(Duke University), Peter Winter(Duke University), David M. Lonard(Baylor College of Medicine), Jacob P. Hoj(Duke University), Grace R. Anderson(Duke University), Samuel H. Gruber(Duke University), Li Qin(Baylor College of Medicine), Benjamin Mayro(Duke University)
Cited by 0
Related Papers
Draft genome sequence of chickpea (Cicer arietinum) provides a resource for trait improvement
|Nature Biotechnology|2013|1.3k
The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level
|Oncogene|2008|852
Metabolic programming and PDHK1 control CD4+ T cell subsets and inflammation
|Journal of Clinical Investigation|2014|717
Metformin, Independent of AMPK, Induces mTOR Inhibition and Cell-Cycle Arrest through REDD1
|Cancer Research|2011|620